下颌下腺移位预防口咽癌放疗所致口干症:调强放疗时代的剂量学影响
研究评估下颌下腺移位对现代调强放疗计划剂量学的影响。18例口咽癌患者行下颌下腺移位后接受调强放疗,并基于基线下颌下腺位置重新优化计划。结果显示移位与否的平均下颌下腺剂量(27.53 Gy vs 29.61 Gy)和总唾液腺剂量(26.12 Gy vs 26.41 Gy)均无统计学显著差异(均 p > 0.05)。结论认为调强放疗可能降低下颌下腺移位对放射性口干症风险的益处。
要点
- 下颌下腺移位与否的平均下颌下腺剂量无统计学显著差异(27.53 Gy vs 29.61 Gy,p > 0.05)。
- 总唾液腺剂量在移位与未移位计划间无统计学显著差异(26.12 Gy vs 26.41 Gy,p > 0.05)。
- 调强放疗可能降低下颌下腺移位对放射性口干症风险的益处。
核心结论
- 下颌下腺移位与否的唾液腺剂量相似,调强放疗可能降低下颌下腺移位对放射性口干症风险的益处。
研究设计与样本
- 18例口咽癌患者行下颌下腺移位后接受调强放疗,并基于基线下颌下腺位置生成重新优化计划,比较临床计划与重新优化计划的平均唾液腺、口腔和喉剂量。
主要发现
- 移位与未移位计划的平均下颌下腺剂量为27.53 Gy vs 29.61 Gy,无统计学显著差异(p > 0.05)。
- 移位与未移位计划的总唾液腺剂量为26.12 Gy vs 26.41 Gy,无统计学显著差异(p > 0.05)。
- 口腔和喉的平均剂量在移位与未移位计划间无统计学显著差异。
- 肿瘤部位、靶区是否跨越中线、分期及唾液腺体积均与平均剂量无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Submandibular gland (SMG) transfer decreased radiation-associated xerostomia in the 2/3-dimensional radiotherapy era. We evaluated the dosimetric implications of SMG transfer on modern intensity modulated radiotherapy (IMRT) plans. METHODS: Eighteen oropharynx cancer patients underwent SMG transfer followed by IMRT; reoptimized plans using the baseline SMG location were generated. Mean salivary gland, oral cavity, and larynx doses were compared between clinical plans and reoptimized plans. RESULTS: No statistically significant difference in mean SMG dose (27.53 Gy vs. 29.61 Gy) or total salivary gland dose (26.12 Gy vs. 26.41 Gy) was observed with or without SMG transfer (all p > 0.05). Mean oral cavity and larynx doses were not statistically different. Neither tumor site, target volume crossing midline, stage, nor salivary gland volumes were associated with mean doses. CONCLUSIONS: Salivary gland doses were similar with or without SMG transfer. IMRT likely decreases the benefit of SMG transfer on the risk of radiation-associated xerostomia.
引用
- Kutuk T, McAllister NC, Rzepczynski AE, et al. Submandibular gland transfer for the prevention of radiation-induced xerostomia in oropharyngeal cancer: Dosimetric impact in the intensity modulated radiotherapy era. Head Neck. 2022. PMID: 35243719. doi:10.1002/hed.27021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。